2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
270股Bio股价因百时美施贵宝合作的癌症免疫疗法的积极数据而上涨
- Bristol Myers Squibb Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma.
- The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen.
- The interim analysis demonstrated a statistically significant improvement in progression-free survival.
- Related Content: Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
- Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens.
- Follow-up for overall survival, a key secondary endpoint, remains ongoing.
- No new safety signals were reported in this study.
- The FDA approved Abecma in March 2021 for relapsed or refractory multiple myeloma after four or more prior lines of therapy.
- Abecma generated $72 million as U.S. commercial revenue in 2Q, split evenly between 2seventy and BMS.
- 2seventy said it is on track toward the upper end of $250-$300M revenue guidance for 2022.
- TSVT ended the June quarter with $399 million in cash. It revised 2022 net cash spend to $245-265 million with a cash runway into 2025.
- Price Action: TSVT shares are up 10.80% at $18.50 during the premarket session on the last check Wednesday.
- Bristol Myers Squibb Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) have announced topline results from KarMMa-3 Phase 3 trial of Abecma (idecabtagene vicleucel) for multiple myeloma.
- The trial compared Abecma to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy and refractory to the last regimen.
- The interim analysis demonstrated a statistically significant improvement in progression-free survival.
- Related Content: Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
- Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens.
- Follow-up for overall survival, a key secondary endpoint, remains ongoing.
- No new safety signals were reported in this study.
- The FDA approved Abecma in March 2021 for relapsed or refractory multiple myeloma after four or more prior lines of therapy.
- Abecma generated $72 million as U.S. commercial revenue in 2Q, split evenly between 2seventy and BMS.
- 2seventy said it is on track toward the upper end of $250-$300M revenue guidance for 2022.
- TSVT ended the June quarter with $399 million in cash. It revised 2022 net cash spend to $245-265 million with a cash runway into 2025.
- Price Action: TSVT shares are up 10.80% at $18.50 during the premarket session on the last check Wednesday.
- 百时美施贵宝公司(纽约证券交易所代码：BMY)和270 Bio Inc.纳斯达克公司(Temasek Holdings：TSVT)宣布了Abecma(依达卡他汀)治疗多发性骨髓瘤的KarMma-3期3期试验的主要结果。
- 这项试验比较了Abecma与标准联合疗法在成人复发和难治性多发性骨髓瘤患者中的作用，这些患者在之前的两到四个系列治疗后，对最后一个方案无效。
- 中期分析显示，无进展存活率在统计学上有显著改善。
- 相关内容： 百时美施贵宝，270拔下多个骨髓瘤CAR-T的插头，Abecma销售势头增强
- 与标准方案相比，使用Abecma的治疗还显示总应答率的关键次要终点有所改善。
- 作为一个关键的次要终点，总存活率的后续行动仍在进行中。
- 在这项研究中没有新的安全信号报道。
- FDA于2021年3月批准Abecma用于复发或难治性多发性骨髓瘤，此前曾接受过四种或四种以上的治疗。
- Abecma在第二季度创造了7200万美元的美国商业收入，在270和BMS之间平均分配。
- 270表示，它正朝着2022年2.5亿至3亿美元营收指引的上限迈进。
- 截至6月底的季度，TSVT的现金为3.99亿美元。该公司将2022年的净现金支出修正为2.45亿至2.65亿美元，并将现金转移到2025年。
- 价格行动：在周三最后一次检查的盘前交易中，TSVT股价上涨10.80%，至18.50美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！